Beam Therapeutics is trading 4.49% higher at $25.60 on October 5, 2026, with broader market gains appearing to support the move. - The S&P 500 is up 0.70% and the Nasdaq Composite 1.04%, supporting a possible risk-on backdrop. - Search results surfaced no clear company-specific announcement dated October 5. - BEAM-302 clinical data highlighted in available coverage was presented at the ERS Congress on September 8, so it does not establish a new catalyst for this session.